Institutions disagree (3 filers, 36% apart) — shown at its later-stage round, Jan 2026 ($920.0M post-money).
- ·27 fund marks: filer, period, implied $/share
Membership and data by Private Market View
Valuation timeline
0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026Membership and data by Private Market View
Parabilis Medicines funding history
3 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Jan 2026 | Later Stage VC (Series F) | $305.0M | ▮ | ▮ |
| Jan 2025 | Later Stage VC (Series E) | $145.0M | ▮ | ▮ |
| Nov 2022 | Later Stage VC (Series D) | $178.0M | ▮ | ▮ |
Membership and data by Private Market View
Parabilis Medicines valuation
Parabilis Medicines is valued at approximately $920 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Jan 2026, at a $920 million post-money valuation.
Recent activity
In the last 90 days, Parabilis Medicines's record added 8 institutional fund marks (latest period Jul 2026).
How much has Parabilis Medicines raised?
Parabilis Medicines has raised $812 million across 3 recorded rounds since 2022. The largest was a $305 million Series F in Jan 2026.
Institutional holders and vehicles
4 SEC-registered funds reported 27 fair-value marks on Parabilis Medicines between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Neurona Therapeutics ($1.1 billion), Bluejay Therapeutics ($820 million) and Abcuro ($700 million).
How Parabilis Medicines's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Parabilis Medicines, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by institutional fund marks. Question about this number? Full methodology →
Frequently asked about Parabilis Medicines
- What is Parabilis Medicines worth?
- Parabilis Medicines is valued at $920.0M as of Oct 2026. Institutions disagree (3 filers, 36% apart) — shown at its later-stage round, Jan 2026 ($920.0M post-money).
- How much has Parabilis Medicines raised?
- Parabilis Medicines has raised $812.0M in total funding across 3 recorded rounds.
- When did Parabilis Medicines last raise?
- Parabilis Medicines last raised in Jan 2026 (Later Stage VC (Series F)), raising $305.0M.